Article Abstract

First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC

Authors: Biagio Ricciuti, Rita Chiari


Molecular profiling in patients with newly diagnosed advanced non-small cell lung cancer (NSCLC) has become routine in clinical practice, allowing us to provide the most effective treatment to individuals harboring actionable genetic alterations.